Rivaroxaban PBS start date revealed

Manufacturer Bayer confirmed rivaroxaban (Xarelto) would be listed for the prevention of stroke in patients with non-valvular atrial fibrillation as of next month as well as for the treatment and prevention of pulmonary embolism.

Last month Health Minister Tanya Plibersek announced the extended indications had been approved by Cabinet but gave no listing date.

Sydney cardiologist Professor Andrew Sindone said the decision was important “at a time when the number of Australians living with irregular heart beat is at an all-time high”.

“Having this next generation treatment readily

Latest

Trending